PROGEN signs non-exclusive distribution agreement for sales of research antibody products
Heidelberg, April 29, 2021 – PROGEN Biotechnik GmbH, established manufacturer of premium research antibodies and AAV gene therapy tools, has signed a non-exclusive distribution agreement with Thermo Fisher Scientific for selected proprietary antibodies, including top-selling immunochemicals.
Since 1983, PROGEN has developed a widely cited portfolio of over 1.000 primary and secondary antibodies for basic and applied life sciences. Sales channels include the company’s online shop and the collaboration with global distributors. As a leading supplier of research materials, Thermo Fisher will now offer a choice of 371 primary antibodies globally. Among them are top-selling products in biomedical research and development, such as lipid metabolism, cytoskeleton, cell adhesion, or oncology that cover the full range of immunochemical applications. PROGEN antibodies are available with full service and support from Thermo Fisher Scientific, also through e-procurement systems.
Joint Managing Directors Katja Betts and Maik Lander welcome the partnership: “We look forward to tapping the sales power of a leading life science manufacturer to make our research antibody product widely available in a competitive global market.”
After focusing for more than three decades on research antibody markets, PROGEN is currently exploring other life science sectors and further expanding its leading role in the AAV gene therapy market to enable safe and effective treatments.